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Summary
Tumor necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL) triggers apoptosis selectively in tumor cells through interaction
with TRAIL-R1/DR4 or TRAIL-R2/DR5 and this process is considered a promising avenue for cancer treatment. TRAIL resistance,
however, is frequently encountered and hampers anti-cancer activity. Here we show that whereas H460 non-small cell lung cancer
(NSCLC) cells display canonical TRAIL-dependent apoptosis, A549 and SW1573 NSCLC cells are TRAIL resistant and display pro-
tumorigenic activity, in particular invasion, following TRAIL treatment. We exploit this situation to contrast TRAIL effects on the
kinome of apoptosis-sensitive cells to that of NSCLC cells in which non-canonical effects predominate, employing peptide arrays
displaying 1024 different kinase pseudosubstrates more or less comprehensively covering the human kinome. We observed that failure
of a therapeutic response to TRAIL coincides with the activation of a non-canonical TRAIL-induced signaling pathway involving,
amongst others, Src, STAT3, FAK, ERK and Akt. The use of selective TRAIL variants against TRAIL-R1 or TRAIL-R2 subsequently
showed that this non-canonical migration and invasion is mediated through TRAIL-R2. Short-hairpin-mediated silencing of RIP1 kinase
prevented TRAIL-induced Src and STAT3 phosphorylation and reduced TRAIL-induced migration and invasion of A549 cells.
Inhibition of Src or STAT3 by shRNA or chemical inhibitors including dasatinib and 5,15-diphenylporphyrin blocked TRAIL-induced
invasion. FAK, AKT and ERK were activated in a RIP1-independent way and inhibition of AKT sensitized A549 cells to TRAIL-
induced apoptosis. We thus identified RIP1-dependent and -independent non-canonical TRAIL kinase cascades in which Src and AKT
are instrumental and could be exploited as co-targets in TRAIL therapy for NSCLC.
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Introduction
Lung cancer is the leading cause of cancer-related mortality
worldwide (Field and Duffy, 2008). Non-small cell lung cancer
(NSCLC) accounts for 85% of all lung cancer cases. Although
several attempts have been made to develop effective treatment
strategies to combat lung cancer, still overall 5-year prognosis is
less than 15% in NSCLC (Jemal et al., 2010). Despite recent
successes in sub-populations of NSCLC patients using targeted
agents, such as inhibitors of epidermal growth factor signaling
(EGF) in patients with mutated EGF receptors, new therapies are
urgently needed for improving treatment (Herbst et al., 2008). An
attractive approach for the treatment of NSCLC is provided
through the TRAIL receptors.
TRAIL receptors are attractive targets as their stimulation
selectively mediates apoptosis activation in tumor cells while
sparing normal cells (Gonzalvez and Ashkenazi, 2010). Apoptosis
activation is mediated via two of five known TRAIL receptors,
TRAIL-R1 (DR4) and TRAIL-R2 (DR5), whereas TRAIL-R3
(DcR1) and TRAIL-R4 (DcR2) are thought to encode non-
functional receptors, also named decoy receptors. A fifth receptor
is osteoprotegerin that acts as a soluble receptor. Apoptosis
activation occurs upon ligand-induced TRAIL-R1 or TRAIL-R2
clustering leading to the assembly of the death-inducing signaling
complex (DISC). In the DISC, Fas-associated protein with death
domain (FADD) binds procaspase 8 or 10 in order to produce
active caspase 8 subsequently leading to effector caspases
activation and apoptosis (Gonzalvez and Ashkenazi, 2010).
Recombinant TRAIL preparations and TRAIL receptor
specific agonistic antibodies have been produced that potently
eradicate tumor cells of different origins, including NSCLC, and
showed efficacy in various preclinical models (Stegehuis et al.,
2010). Anti-cancer action of TRAIL receptor targeted agents
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when applied as single agents, however, is frequently hampered
by resistance in tumor cells. For example, approximately half of
the NSCLC tumor cells are resistant to the apoptosis-inducing
effect of TRAIL unless applied in combination with various
conventional or biological agents resulting in sensitive cells
(Stegehuis et al., 2010). Thus, although currently clinical testing
of TRAIL receptor targeted agents shows only moderate efficacy,
there is optimism that combination strategies with other
therapeutics will overcome resistance and increase therapeutic
benefit.
In contrast to its apoptosis-inducing activity, TRAIL has been
reported to activate non-apoptotic signaling. In resistant
tumor cells TRAIL receptors have been reported to activate
pro-inflammatory (NF-kB), pro-survival (PI3K/AKT) and
proliferation [mitogen-activated protein kinase (MAPK)]
pathways (Newsom-Davis et al., 2009). Activation of these
non-apoptotic signaling pathways involves the recruitment of a
number of proteins to the receptors, such as receptor-interacting
protein 1 (RIP1), TNF receptor associated factor 2 (TRAF2),
TNF receptor type 1-associated death domain (TRADD) and
NEMO/IKK-c, thus forming secondary intracellular complexes
(Jin and El-Deiry, 2006; Varfolomeev et al., 2005). The precise
compositions and sequence of formation of the multiprotein
complexes in which these factors reside are currently elusive.
However, the death domain containing kinase RIP1 was shown to
play a pivotal role in the activation of NF-kB, JNK, p38 and
ERK1/2 by TRAIL, and in the activation of necroptosis by TNF
(Declercq et al., 2009; Meylan and Tschopp, 2005). More
recently TRAIL has also been implicated in the promotion of
tumor cell invasion in pancreatic ductal adenocarcinoma and
colorectal cancer models (Hoogwater et al., 2010; Trauzold et al.,
2006), further illustrating pro-tumorigenic/non-canonical activity
of TRAIL in resistant tumor cells. Clearly, the dual activity of
TRAIL can hamper its clinical activity and delineating these
unwanted effects is essential for developing strategies to revert
them into pro-apoptotic signals. Together, these considerations
prompted us for a systematic evaluation of the nature of these
non-canonical TRAIL-dependent pathways.
In the present study we have examined the possible pro-
tumorigenic effects of TRAIL on NSCLC cells. Particularly we
found that TRAIL induces migration and invasion of TRAIL-
resistant NSCLC cells. A kinome profiling strategy was used to
dissect underlying molecular mechanisms and the identified
kinases were further examined for involvement in non-canonical
TRAIL signaling. Collectively, our results identified a novel
TRAIL-induced Src-STAT3-dependent tumor cell migratory
pathway and imply enhanced therapeutic benefit of TRAIL
therapy when combined with Src and PI3K/Akt inhibition.
Results
TRAIL induces a spectrum from pro-apoptotic to
pro-invasive responses in different NSCLC cells
TRAIL resistance of cancer cells hampers therapeutic exploitation
of the TRAIL apoptotic pathway and may even provoke
counterproductive effects. Also in vitro, different NSCLC cell
lines differ markedly in their sensitivity to TRAIL as judged by the
capacity of a 24 h TRAIL treatment to diminish cell viability as
measured in MTT (tetrazolium dye) assays (Fig. 1A,B). Whereas
H460 cells are highly sensitive for TRAIL [50% inhibition of cell
growth (IC50)<10 ng/ml], H322 cells require higher concentrations
to respond with cell death to TRAIL treatment (IC50<81 ng/ml),
and SW1573 and A549 cells seem incapable of inducing an
apoptotic response to TRAIL (IC50.200 ng/ml). Importantly,
resistance to cell death is associated with TRAIL-induced pro-
invasive effects in NSCLC. In wound healing assays, TRAIL
treatment resulted in two- to threefold increased migratory activity
of A549 cells when compared to untreated cells (Fig. 2A,B). Also,
SW1573 cells showed an increase in migration activity in this assay
upon TRAIL challenge, whereas TRAIL failed to induce migration
in H322 and H460 cells in line with apoptosis activation in these
cells. MTT assays performed in parallel showed that the enhanced
‘wound healing’ in A549 cells is not due to a TRAIL-mediated
increase in proliferation (Fig 2E). Consistently, a decreased
potential to respond to TRAIL stimulation with apoptosis is
associated with increased invasion as detected in Matrigel-
Transwell assays. TRAIL-apoptosis-resistant A549 cells exhibited
approximately a twofold increase in invasive capacity following
TRAIL stimulation when compared to untreated cells (Fig. 2C,D).
Accordingly, SW1573 displayed enhanced invasion following
TRAIL treatment, whereas H322 cells were not affected and H460
cells showed reduced invasion – correlating with the pro-apoptotic
activity of TRAIL. We conclude that using this panel of NSCLC
cell lines we can study a spectrum of TRAIL responses, ranging
from full therapeutic sensitivity (H460 cells) to a cell line that
almost exclusively displays non-canonical pro-oncogenic effects
following TRAIL treatment (A549 cells), and we decided to exploit
this situation to obtain fundamental insight into the molecular basis
of the differential TRAIL response. Experiments were therefore
initiated to characterize the signal transduction events involved.
Kinome profiling of TRAIL signaling in resistant and
sensitive cells
The apparent dichotomy between canonical pro-apoptotic TRAIL
responses in H460 cells and non-canonical pro-invasive TRAIL
responses in A549 cells allowed us to delineate the signal
transduction elements involved in TRAIL signaling. We resorted
to using kinome profiling employing peptide arrays exhibiting 960
Fig. 1. Cytotoxic effects of TRAIL in different NSCLC
cell lines. (A) Cell growth was measured using an MTT
assay following treatment with increasing concentrations of
TRAIL for 24 h. (B) Calculated IC50 values for TRAIL in
the different NSCLC cells.
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different kinase pseudosubstrates that provide comprehensive
descriptions of the cellular kinome. This allowed us to contrast
TRAIL-induced kinomic changes in the canonically signaling
H460 cells to those in the non-canonical signaling A549 cells. To
this end, cells were treated for 15 min either with vehicle control or
with 50 ng/ml TRAIL in order to detect early kinase activation
events. The obtained kinome profiles of treated and untreated cells
of each cell line revealed substantial differences between TRAIL-
induced kinase activity in A549 and H460 cells (for a selection see
Table 1). Importantly, a signal transduction cascade emerged in
which A549 cells respond to TRAIL by activation of a proximal
tyrosine kinase activity associated with several signaling events
like increased JAK2 signaling to STAT3 and enhanced PI3K
activity led to activation of the Akt/mTOR/S6 kinase signaling
pathway. There is also increased activity of Rac, Rho and Src
signaling able to enhance FAK activity and phosphorylation to
other cytoskeleton remodeling proteins (e.g. cortactin, vimentin;
see Table 1) and increased activity of the Raf/MEK/ERK signaling
cassette.
Non-canonical TRAIL-dependent kinase activities are
reflected in altered levels of target protein phosphorylation
The kinome profiling assay measures kinase activities, but within
a cell kinase activities are counterbalanced by the enzymatic
activity of phosphatases. Hence it is important to establish if the
differences in kinase activities as determined by kinome profiling
are reflected in altered levels of phosphorylation of target
proteins. In accordance with the PepChip results, western blot
experiments revealed that already within 5 minutes after TRAIL
treatment Src and ERK were phosphorylated, whereas Akt,
STAT3 and FAK phosphorylation were detectable at 10 to
15 min post-treatment in A549 cells (Fig. 3A). However, not all
identified possible targets or upstream kinases could be
corroborated. For example, TRAIL-induced VAV2 and JAK2
phosphorylation was not observed by western blotting, while we
did not find evidence of activation of ROCK (not shown). Basal
and TRAIL-induced phosphorylation of a number of kinases,
including Src, Akt, ERK, FAK and STAT3, was variable in the
other cell lines (Fig. 3B). In TRAIL-resistant SW1573 cells
increases in phosphorylation of Src ERK, and FAK by TRAIL
were seen. In H460 no detectable effects were observed and in
intermediate TRAIL-sensitive H322 cells, ERK phosphorylation
was slightly elevated after TRAIL exposure (Fig. 3B). Thus the
non-canonical TRAIL signaling pathway identified by kinome
profiling is reflected in meaningful changes in target protein
phosphorylation.
Non-canonical TRAIL responses are mediated through
the TRAIL-R2
Earlier we generated TRAIL variants that selectively engage
either TRAIL-R1 or TRAIL-R2, named 4C7 and DHER,
respectively (Reis et al., 2010; van der Sloot et al., 2006). We
found these variants to be more potent than wild-type TRAIL in
triggering apoptosis in a tumor cell line-dependent fashion. We
now employed these variants to determine the TRAIL receptor
mainly responsible for the induction of non-canonical pro-
invasive properties of TRAIL. A549 cells express both TRAIL-
R1 and -R2, whereas decoy receptors are hardly detectable on the
Fig. 2. TRAIL induces migration and invasion in resistant NSCLC cells. (A) Migration of H460, H322, SW1573 and A549 cells treated for 15 min with
TRAIL. (B) The wound closure was measured after 8 h, as shown in a representative wound-healing experiment. (C) Effect of TRAIL on the invasiveness of
NSCLC cell lines assessed with Matrigel-Transwell assays for the determination of invasiveness as shown in D. (E) Cell growth determined by MTT assays of
cells treated with 50 ng/ml TRAIL for 15 min and further culturing for 8 h with refreshed medium.
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cell surface (Fig. 4A), in agreement with our previous findings
(Voortman et al., 2007). As shown in Fig. 4B,C, migration and
invasion of A549 cells is enhanced when stimulated with the
TRAIL-R2 selective ligand (DHER), and not by TRAIL-R1
selective 4C7. Thus, the non-canonical migratory and invasive
features of TRAIL in resistant NSCLC cells are predominantly
mediated by TRAIL-R2. Furthermore, comparing DHER- with
TRAIL-treated A549 cells showed a similar kinase
phosphorylation profile (Fig. 4D).
The migratory and invasive effects of TRAIL are mediated
by RIP1 and involve activation of Src
We next examined the role of RIP1 kinase in signaling pathways
that mediate migration and invasion. RIP1, part of the non-
apoptotic signaling complex, is known to be involved in TRAIL-
induced kinase activation although its precise role is not well
understood (Falschlehner et al., 2007; Varfolomeev et al., 2005).
RIP1 was silenced using a selective shRNA in A549 and H460
cells and knockdown was confirmed by western blotting
(Fig. 5A). A549-shRIP1 cells clearly showed a decrease in
TRAIL-dependent migration in wound healing assays (Fig. 5B).
The invasive effect of TRAIL was also abrogated in the absence
of RIP1 (Fig. 5C). In contrast, there were no differences in
TRAIL-dependent migration and invasion in H460-shRIP1 cells
compared to control cells. RIP1 knockdown in A549 cells did not
result in a detectable increase in TRAIL sensitivity (Fig. 5D).
The involvement of RIP1 in TRAIL-induced kinase activation was
examined in more detail. As depicted in Fig. 5E, TRAIL-induced Src
and STAT3 phosphorylation is abrogated in A549-shRIP1 cells.
However, RIP1 depletion did not affect the phosphorylation of Akt,
ERK and FAK following TRAIL treatment. In H460 cells
phosphorylation of Src, Akt and ERK was not significantly altered
(Fig. 5F). The abrogation of TRAIL-induced migration/invasion in
A549-shRIP1 cells together with a lack of Src and STAT3 activation
is suggestive of a role of these kinases in controlling the metastasis-
prone events.
TRAIL-dependent activation of a RIP1-Src-STAT3 cascade
mediates invasive behavior
To further investigate the role of Src in mediating TRAIL-
induced migration/invasion, Src expression was silenced with
shRNA in A549 cells. In these cells TRAIL-induced migration
and invasion was completely inhibited (Fig. 6A,B). Knockdown
of Src did not result in an increase in cell death after TRAIL
treatment when compared to the empty vector control (Fig. 6C).
Thus, the observed decrease in migration and invasion was not a
consequence of apoptosis induction. Furthermore, three different
Src inhibitors, PP2, dasatinib and saracatinib were employed at
concentrations reported to be optimal for selective inhibition of
Src as described previously by others (Johnson et al., 2005;
Purnell et al., 2009). As shown in Fig. 6D,E, migration and
invasion by TRAIL was completely repressed with each of the
Src inhibitors. In addition, these inhibitors particularly when
applied at a higher concentration did to some extent enhance
TRAIL-induced apoptosis in A549 cells, most notably dasatinib
(Fig. 6F). In SW1573 cells, Src inhibition by PP2 also repressed
the migratory and invasive effects of TRAIL without
significantly affecting apoptosis (Fig. 6G-I). Further delineation
Table 1. Effects of TRAIL stimulation on kinase activity in TRAIL-sensitive H460 cells and TRAIL-resistant A549 cells
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of the pathway in A549 cells, using the STAT3 inhibitor
5,15-diphenylporphyrin (5,15-DPP) and the RIP1 inhibitor
necrostatin-1, showed attenuation of the migrating and invasive
effects of TRAIL (Fig. 7A,B). Necrostatin-1 did not affect
apoptosis sensitivity in resistant A549 cells (Fig. 7C), which is in
line with shRIP1 knockdown results. Together these results
implicate a TRAIL-induced RIP1-Src-STAT3 cascade to drive
A549 NSCLC cell invasion.
TRAIL-induced kinase activation and effects on migration,
invasion and apoptosis
Finally, we explored possible interactions between the identified
TRAIL-induced kinase cascades. Knockdown of Src in A549
cells prevented, and even decreased, the phosphorylation of
STAT3 after TRAIL application. Also TRAIL-induced FAK
phosphorylation appeared to depend on Src, whereas p-Akt and
p-ERK levels were not affected in A549-shSrc cells (Fig. 8A).
Fig. 3. TRAIL-induced kinase activation in NSCLC cells; confirming kinases identified by PepChip kinase arrays. (A) The indicated kinases were
evaluated for TRAIL-induced phosphorylation in A549 cells over 60 min by western blotting, using antibodies detecting phosphorylated and total kinase. The
numbers between the blots are the ratios of the intensity of bands for the phosphorylated form to the band of the total protein. The untreated control was set at 1.0.
(B) Kinase activation in H460, H322, SW1573 and A549 cells after treatment with 50 ng/ml TRAIL for 15 min, determined by western blotting.
Fig. 4. TRAIL induces migration and invasion in A549 cells
mainly through TRAIL-R2. (A) TRAIL receptor surface
expression in A549 cells determined by FACS analysis.
(B) Effect of TRAIL-R1 (4C7)- and TRAIL-R2 (DHER)-
specific TRAIL variants on migration. (C) Effect of the TRAIL
variants on invasion. Levels of untreated cells were set at 100%.
Values are means 6 s.d. of three experiments. *P,0.05, t-test
compared with CTRL. (D) Western blots showing
phosphorylation status of the indicated kinases in A549 cells
after 15 min treatment with 50 ng/ml DHER.
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On the other hand, inhibition of Akt by LY294002 and ERK by
PD098059 also reduced migration and invasion induced by
TRAIL (Fig. 8B). Interestingly, inhibition of Akt converted
TRAIL resistant A549 cells into apoptosis sensitive cells. In
conclusion, we identified novel parallel branches of TRAIL-
induced kinase activation that mediate metastases-prone and/or
pro-survival effects (see also Fig. 8C).
Discussion
The TRAIL receptor pathway is currently therapeutically
exploited for selective activation of apoptosis in tumor cells.
However, stimulation of the TRAIL receptors in preclinical
models can also activate unwanted non-apoptotic/non-canonical
signaling leading to proliferative, pro-survival and even pro-
invasive effects. In the present study using a panel of TRAIL
sensitive and resistant NSCLC cell lines we demonstrated non-
canonical signaling in resistant cells that enhanced their
migratory and invasive properties. Interestingly, whereas the
NSCLC cells express both TRAIL-R1 and TRAIL-R2 on their
cell surface we only found TRAIL-R2/DR5 to mediate these
effects, thus illustrating that the TRAIL receptors have different
signaling properties. Intriguing in this respect is an earlier
described correlation of high TRAIL-R2 levels in advanced stage
NSCLC patients with increased risk of death (Spierings et al.,
2003). The underlying causes of differential signaling are still
elusive and are subject of further studies.
Using peptide arrays exhibiting 1024 specific consensus
sequences for protein kinases we identified substrates and
corresponding kinases that are stimulated following TRAIL
exposure in A549 cells contrasting findings in sensitive H460
cells. Subsequent confirmation of kinase phosphorylation by
western blotting allowed us to identify several kinases that are
activated by TRAIL in resistant A549 cells (see also Fig. 8C for a
schematic overview). In particular activation of the Src-STAT3
Fig. 5. TRAIL-induced migration and invasion, and Src-STAT3 activation is RIP1 dependent. (A) Expression of RIP1 was effectively silenced by a specific
shRNA in H460 and A549 cells, as determined by western blotting. (B) TRAIL-dependent cell migration was determined in wound healing assays.
(C) Invasiveness, as determined by Matrigel-Transwell assays. (D) The effect of RIP1 knockdown on TRAIL-induced apoptosis in A549 and H460 cells.
(E,F) Western blots showing the effect of RIP1 knockdown on TRAIL-dependent kinase activation (50 ng/ml TRAIL for 15 min) in A549 cells (E) and H460
cells (F). Values are means 6 s.d. of three experiments. *P,0.05, t-test, compared with each other.
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axis was important for mediating TRAIL-induced migration and
invasion. The non-receptor protein tyrosine kinase Src is a known
activator of signal transduction pathways controlling various key
cellular processes such as cell division, proliferation, survival and
motility (Gallick, 2004). Elevated Src protein levels and/or
kinase activity have been reported in 50-80% of lung cancer
cases and correlates with poor patient survival (Mazurenko et al.,
1992). Src is a known mediator of tumor cell migration and
invasion as it leads to reorganization of the cytoskeleton and
modulation of the cell adhesion system (Guarino, 2010).
Downstream of Src we identified STAT3 as a mediator of
migration. This is not unprecedented since recently Src-induced
STAT3 activation has been implicated in the formation of
podosome structures in primary murine cells facilitating cell
migration (Mukhopadhyay et al., 2010). STAT3 inhibitors have
also been reported to inhibit the migration of prostate cancer cells
(Abdulghani et al., 2008). Mechanisms described by which
STAT3 can promote cell migration include binding of STAT3 to
bPIX leading to Rac1 activation (Teng et al., 2009) and direct
phosphorylation of fascin, an actin-bundling protein, by STAT3
(Snyder et al., 2011). The precise downstream effectors of
STAT3 signaling in TRAIL-induced migration/invasion in
NSCLC cells remains to be explored. Another mechanism
through which Src can stimulate invasion is via the activation
of epithelial-mesenchymal transition (EMT) (Boyer et al., 2002).
The acquisition of mesenchymal properties by epithelial cells
characterized by for example loss of E-cadherin and gain of
fibronectin expression has been found to stimulate tumor cell
dispersion (Kalluri and Weinberg, 2009). However, we did not
detect clear changes in the expression of these markers in
response to TRAIL in NSCLC cells (not shown). Other Src-
dependent signals that have been implicated in migration include
activation of the Rho/ROCK/LIMK, Ras/MAPK, PI3K/Akt,
FAK/paxillin/CAS pathways (Guarino, 2010). Although the
kinome analyses identified possible ROCK activity after
TRAIL exposure, we were not able to confirm ROCK
Fig. 6. Inhibition of Src blocks TRAIL-induced migration and invasion of A549 and SW1573 cells. (A) Src knockdown using specific shRNA (confirmed by
western blotting in insert) blocks TRAIL-induced migration in wound healing assays. (B) Src knockdown inhibits TRAIL-induced invasion in Matrigel-Transwell
chamber assays. (C) Silencing Src does not result in an increase in cell death after TRAIL treatment in A549 cells. (D-H) A549 cells were incubated with or
without chemical inhibitors of Src, PP2 (1 mM), dasatinib (0.01 mM) or saracatinib (1 mM), to determine the effects on migration (D), invasion (E) and cell death
(F) of treatment with 50 ng/ml TRAIL. (G-I) In SW1573 cells PP2 (1 mM) blocks TRAIL-induced migration (G), and inhibits the invasive effect of TRAIL
(H) but has no effect on TRAIL-induced apoptosis (I). Values are means 6 s.d. of three independent experiments. *P,0.05, t-test, compared with 50 ng/ml
TRAIL.
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activation in western blots and co-treatment with a ROCK
inhibitor did not prevent TRAIL-induced invasion (not shown).
On the other hand, knockdown of Src in A549 cells inhibited
TRAIL-dependent FAK phosphorylation suggesting a possible
role of this pathway as well. FAK is a non-receptor protein
tyrosine kinase known to stimulate migration/invasion when in
complex with Src (van Nimwegen and van de Water, 2007). Of
note, in SW1573 cells TRAIL resulted in Src-dependent FAK
phosphorylation, but not STAT3 phosphorylation. This may be
related to the smaller stimulatory effect of TRAIL on migration/
invasion in SW1573 cells (1.5-fold) when compared to A549
cells (2- to 3-fold). Inhibition of ERK did partially suppress
invasive behavior of A549 cells, however, TRAIL-induced ERK
phosphorylation was independent of Src as was also the case for
Akt activation. Active Src has the ability to phosphorylate
caspase-8 at tyrosine 380 resulting in blocking of its pro-
apoptotic function (Cursi et al., 2006). However, we could not
detect phosphorylated procaspase-8 (not shown) and shRNA-
mediated knockdown or chemical inhibition of Src by dasatinib
and saracatinib did prevent TRAIL-induced invasion, but failed
to effectively sensitize for apoptosis in A549 cells, pointing to
other mechanisms of resistance.
TRAIL stimulatory effects on tumor cell migration and
invasion have been previously reported to be mediated by NF-
kB in apoptosis resistant cholangiocarcinoma cancer cells
(Ishimura et al., 2006), and by TRAIL-dependent upregulation
of interleukin-8 and chemoattractant protein 1 in pancreatic
ductal adenocarcinoma cells (Trauzold et al., 2006). A more
recent study has shown that TRAIL-induced migration in colon
cancer cells involves oncogenic K-Ras and Raf-1 that convert
death receptors into invasion-inducing receptors by suppressing
the ROCK/LIM kinase/cofilin pathway (Hoogwater et al., 2010).
However, the K-Ras status not always predicts the outcome of
death receptor signaling, since for example H460 NSCLC cells in
our study are highly sensitive for TRAIL-induced apoptosis
despite the presence of oncogenic K-Ras. Thus, in NSCLC cells
TRAIL-induced Src activation appears to be the main route
responsible for migration and invasion.
RIP1 is a serine threonine kinase belonging to the RIP family
involved in promoting pro-survival, inflammatory and pro-
apoptotic signals depending on the signal and tumor type
(Meylan and Tschopp, 2005). RIP1 is part of the secondary
complex and has been associated with non-apoptotic functions of
TRAIL (Varfolomeev et al., 2005). To understand the role of
RIP1 in our model shRNA-mediated knockdown as well as
RIP1 inhibition by necrostatin-1 revealed prevention of
TRAIL-induced Src-STAT3 activation and migration/invasion,
corroborating the importance of this pathway. In contrast to a
previous report we did not observe sensitization for TRAIL-
induced apoptosis in A549 RIP1 knockdown cells (Song et al.,
2007). Regarding Akt activation, in prostate adenocarcinoma
cells TRAIL-dependent Src activation has been reported to result
in activation of PI3K-Akt signaling (Song et al., 2010). We found
in NSCLC cells TRAIL to activate a Src-independent mechanism
responsible for Akt activation, and moreover, Akt and also ERK
activation was independent of RIP1. The activation of Akt and
ERK may be a more indirect consequence of TRAIL pathway
activation. For example, in colorectal cancer cells TRAIL was
found to activate EGFR and HER2 through Src family kinases
(SFK) that in turn activated the cell surface protein A Disintegrin
And Metalloproteinase-17 (ADAM-17) also known as Tumor
Necrosis Factor Converting Enzyme (TACE) leading to cleavage
and shedding of TGF-a. Subsequently, TGF-a activated the
EGFR/HER2 pro-survival signaling pathways in an autocrine and
paracrine manner (Van Schaeybroeck et al., 2008). Furthermore,
we found TRAIL to be able to phosphorylate FAK in RIP1
knockdown NSCLC cells, in which TRAIL-induced Src
activation was prevented. Thus, FAK can be activated in a
RIP1-dependent and -independent way, indicating more complex
interactions at the level of RIP1, Src and FAK. In this study we
identified Akt as an important mediator of TRAIL resistance in
NSCLC cells. This confirms earlier studies where the PI3K
inhibitors wortmannin or LY-294002 and the Akt-inhibitor
perifosine were shown to cooperate with rhTRAIL to induce
apoptosis in NSCLC cells involving increased TRAIL-R2
expression and a reduction of c-FLIP levels (Elrod et al., 2007;
Kandasamy and Srivastava, 2002).
Taken together, it can be concluded from our work that TRAIL
non-canonical signaling in NSCLC involves a parallel activation
of RIP1-dependent and -independent mechanisms that stimulate
Fig. 7. Inhibition of STAT3 and RIP1 blocks migration/invasion induced
by TRAIL in A549 cells. (A) A549 cells were incubated with or without
chemical inhibitors of STAT3 (5,15-DPP) or RIP1 (necrostatin-1) and with or
without TRAIL (50 ng/ml). Migration was determined after 8 h with the wound
healing assay. (B,C) Invasion after 8 h (B) and cell death after 24 h (C)
incubation were also determined. Values are means6 s.d. of three independent
experiments. *P,0.05, t-test, compared with 50 ng/ml TRAIL.
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both pro-survival (Akt) and migration/invasion (Src, STAT3)
mechanisms. Although more work is required to evaluate the
unwanted non-canonical effects in other models, our findings
may indicate that care should be taken when using TRAIL
receptor targeting agents for treating patients. Moreover,
treatments with TRAIL agonistic agents in NSCLC may benefit
from combined treatment with PI3K/Akt and Src inhibitors in
order to potentiate antitumor activity and to prevent unwanted
side effects.
Materials and Methods
Cell lines and chemicals
NSCLC cells, H460, H322, SW1573 and A549, obtained from ATCC in 2003,
were cultured as monolayers in RPMI 1640 medium, supplemented with 10% (v/v)
FBS, 100 units/ml penicillin, and 100 mg/ml streptomycin. Cells were maintained
in a humidified 5% CO2 atmosphere at 37 C˚. The cell lines were tested for their
authenticity by short tandem repeat (STR) profiling DNA fingerprinting
(Baseclear, Leiden, The Netherlands). PP2, PD098059 (Sigma-Aldrich, St Louis,
MO, USA), dasatinib and saracatinib (both from LC Laboratories, Woburn, MA,
USA) were dissolved in DMSO to 20 mM stock solutions. LY294002 (Sigma-
Aldrich) was dissolved in DMSO to 10 mM stock solution.
MTT assay
A total of 10,000 cells were seeded in 96-well plates (Greiner Bio-One,
Frickenhausen, Germany). The next day 100 ml medium with or without TRAIL
was added with increasing concentrations to the cells. After 24 h incubation, the
medium was discarded and 50 ml of a MTT solution [0.5 mg/ml (Sigma-Aldrich)
in HBSS] was added and incubated at 37 C˚ for 1.5 h. The formazan crystals were
dissolved using 150 ml dimethyl sulfoxide (DMSO) and absorbance was measured
at 540 nm (Tecan, Ma¨nnedorf, Switzerland). Results are presented as percentage
of viable cells taking the control (untreated cells) as 100% survival. The
concentration resulting in 50% inhibition of cell growth (IC50) was derived from
the growth inhibition curve.
Receptor cell surface expression
Analysis of TRAIL-receptor membrane expression was performed using a flow
cytometer (Epics Elite, Coulter-Electronics, Hialeah, FL, USA). Adherent cells
were harvested by treatment with trypsin and washed twice in PBS containing 1%
BSA. Appropriate concentrations of antibodies dissolved in PBS/1% BSA were
added to the cells. The following antibodies were used to determine TRAIL
receptor membrane expression: TRAIL-R1 (HS101), TRAIL-R2 (HS201), TRAIL-
R3 (HS301), TRAIL-R4 (HS402), all from Alexis. Mouse IgG (DAKO) was used
as isotype control. Subsequently, cells were incubated for 30 min on ice, washed
twice with cold PBS/1% BSA, and incubated with FITC-conjugated rabbit-
antimouse (DAKO, Glostrup, Denmark) for 30 min on ice. After washing, the cells
were analyzed by flow cytometry. Surface expression is shown as a ratio of the
signal of the specific TRAIL-receptor antibody and the negative isotype control
antibody.
Migration assays
Cell migration was determined using the wound healing assay as described
previously (Bijnsdorp et al., 2011). In brief, NSCLC cells were seeded in 96-well
plates and grown till confluence. A 96-well floating-pin transfer device with a pin
diameter of 1.58 mm coming to a flat point at the tip with a diameter of 0.4 mm
(VP Scientific VP-408FH) was used to make the scratches (Yarrow et al., 2004).
TRAIL was added for 15 min and after medium refreshment migration was
monitored. Indicated kinase inhibitors were incubated for 30 min, followed by
15 min incubation with TRAIL. Wounds were captured at 2.56magnification with
a microscope (DMIRB, Leica Microsystems, Wetzlar, Germany), and Q500MC
software (Leica Microsystems) at 0 and 8 h. The wound width at 8 h was measured
in four areas and compared with the initial width at the 0 h time point.
Invasion assays
The invasion assay was carried out by using Transwell chambers with
fluorescence-blocking 8 mm pore polycarbonate filter inserts (no. 35-1152; HTS
Fluoroblock Insert, Falcon, Becton Dickinson Labware, Bedford, MA) in 24-well
plates (Bijnsdorp et al., 2011). The insert was coated overnight at RT with 100 ml
Matrigel (50 ng/ml in PBS; Sigma-Aldrich). The cells were treated for 15 min
with TRAIL. In each insert 200,000 H460 or A549 cells were seeded in serum free
RPMI 1640 medium. For H322 and SW1573 800,000 cells were taken. In the
Fig. 8. The role of Src in TRAIL-induced kinase activation and the effect of Akt and ERK inhibition on migration, invasion and cell death. (A) Western
blots showing the effect of Src knockdown on TRAIL-dependent activation of the indicated kinases. (B) Migration, invasion (at 8 h post-treatment) and
cell death (24 h after treatment) of A549 cells with or without PI3K/Akt inhibition by LY294002 and ERK inhibition by PD098059. *P,0.05, t-test, compared
with 50 ng/ml TRAIL. (C) Schematic representation of the identified kinases involved in non-canonical TRAIL signaling. RIP1-dependent and -independent
mechanisms were found, leading to parallel activation of pro-survival and migration/invasion-promoting pathways.
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bottom compartment, medium containing 10% FCS was added. NSCLC cells were
allowed to invade for 8 h. After 8 h 5 mM calcein-AM (Molecular Probes, Eugene,
OR, USA) was added to the lower compartment for 30 min. Pictures were captured
and fluorescently labeled cells were counted.
Kinome profiling arrays
The PepChipH kinome array (Pepscan Systems, Lelystad, The Netherlands)
consisting of 1024 peptides with specific phosphorylation sites was used to
evaluate the kinome after TRAIL treatment in NSCLC cells, similarly as described
previously (Parikh et al., 2009; van Baal et al., 2006). Lysates generated from
H460 and A549 cells treated with or without TRAIL (15 min) were analyzed in the
assays.
PepChipH data analysis
A PepChipH contains 1024 peptides that are spotted in triplicate. Two slides were
taken for one condition and experiments were performed in duplicate, resulting in
12 data points per condition. The spots were quantified using the ScanAlyze
software and the mean intensity of the 12 data points representing a specific
peptide was calculated. Spots deviating more then 26 standard-deviation were
excluded. Peptides were considered to represent true phosphorylation events when
the average phosphorylation minus 1.96 times the standard deviation of the 12
spots was higher than the value expected from the background distribution. A
value of 1.96 was taken, which yields a P-value of at least 0.05. A list of peptides
was generated by ranking the spots and curve-fitting analysis, resulting in an ‘on’
or ‘off’ call for each peptide used to create provisional signal transduction schemes
as described earlier [van Baal et al., 2006].
Western blotting
Western blot analysis was performed as described before (Bijnsdorp et al., 2011).
The following primary antibodies were used all from Cell Signaling Technology
Inc. (Danvers, MA, USA): anti-p-Src (Tyr416; no. 2101), anti-Src (no. 2109), anti-
p-Akt (Ser473; no. 9271), anti-Akt (no. 9272), anti-p-ERK 42/44 (Thr202/Tyr204;
no. 9101), anti-ERK (no. 9102), anti-p-STAT3 (Ser727; no. 9134), anti-STAT3
(no. 9132) and RIP (no. 3493). b-Actin was from Sigma-Aldrich. The bands were
analyzed and the activities of the kinases were determined by calculating the ratio
between the phosphorylated form and the total kinase.
Gene silencing
For silencing the expression of genes pSUPER.retro was used similarly as described
previously (Brummelkamp et al., 2002). Targeted short hairpin (sh) RNA sequences
were inserted into the BglII and HindIII sites of the pSUPER.retro vector. All cloned
shRNA sequences were verified by DNA sequencing. Retroviruses were packaged
and introduced into cells as described previously (van Leuken et al., 2009). A549 and
H460 cells were retrovirally infected with control pSUPER.retro or pSUPER.retro-
shRIP1 (RIP1-targeting sequence no. 1, 59-GAGCAGCAGTTGATAATGT-39;
RIP1-targeting sequence no. 2 59-TACCACTAGTCTGACGGATAA-39) or
pSUPER.retro-shSrc (59-GGACCTTCCTCGTGCGAGA-39) for 24 h. Infected
cells were selected with 2 mg/ml puromycin.
Cell death measurement
Cell death measurements were performed by FACS analysis as described
previously (Janmaat et al., 2003). In brief, cells were seeded at a density of
400,000 cells/well in 6-well plates. After treatment, cells were trypsinized,
resuspended in medium collected from the matching sample and centrifuged for
5 min at 1200 rpm. Subsequently, cells were stained with propidium iodide
(Sigma-Aldrich) buffer (0.1 mg/ml with 0.1% RNAse A (Qiagen, Venlo, the
Netherlands) in dark on ice. DNA content of the cells was analyzed by FACS
(Becton Dickinson, Immunocytometry Systems, San Jose, CA, USA) with an
acquisition of 10,000 events. The sub-G1 peak was used to determine the extent of
cell death.
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